Synvista Therapeutics will start a phase II clinical trial on their new topical drug SYI-2074, a cream that blocks activities of TNF-alpha. Other TNF-alpha blocking drugs such as Enbrel have all been of the injectable class and have generally been approved only for treatment of moderate to severe psoriasis. SYI-2074 is going to be targeted at mild to moderate psoriasis. Biologics for All! Well, let's make sure the stuff works well before we put our party hats on, but I have to say that the pipeline of drugs under development for psoriasis is chock full of exciting stuff for the near future.